Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant
| Author | Abu-Raddad, Laith J |
| Author | Chemaitelly, Hiam |
| Author | Ayoub, Houssein H |
| Author | Yassine, Hadi M |
| Author | Benslimane, Fatiha M |
| Author | Al Khatib, Hebah A |
| Author | Tang, Patrick |
| Author | Hasan, Mohammad R |
| Author | Coyle, Peter |
| Author | AlMukdad, Sawsan |
| Author | Al Kanaani, Zaina |
| Author | Al Kuwari, Einas |
| Author | Jeremijenko, Andrew |
| Author | Kaleeckal, Anvar Hassan |
| Author | Latif, Ali Nizar |
| Author | Shaik, Riyazuddin Mohammad |
| Author | Abdul Rahim, Hanan F |
| Author | Nasrallah, Gheyath K |
| Author | Al Kuwari, Mohamed Ghaith |
| Author | Butt, Adeel A |
| Author | Al Romaihi, Hamad Eid |
| Author | Al-Thani, Mohamed H |
| Author | Al Khal, Abdullatif |
| Author | Bertollini, Roberto |
| Available date | 2022-01-10T07:35:25Z |
| Publication Date | 2021-10-17 |
| Publication Name | Clinical Infectious Diseases |
| Identifier | http://dx.doi.org/10.1093/cid/ciab909 |
| Abstract | Beta (B.1.351) variant COVID-19 disease was investigated in Qatar. Compared to Alpha (B.1.1.7) variant, odds of progressing to severe disease were 1.24-fold (95% CI: 1.11-1.39) higher for Beta. Odds of progressing to critical disease were 1.49-fold (95% CI: 1.13-1.97) higher. Odds of COVID-19 death were 1.57-fold (95% CI: 1.03-2.43) higher. |
| Language | en |
| Publisher | Oxford Academic |
| Subject | SARS-CoV-2 case-control epidemiology infection severe disease variant |
| Type | Article |
Files in this item
This item appears in the following Collection(s)
-
Biomedical Sciences [738 items ]
-
COVID-19 Research [835 items ]